High–quality iPSC derived lines from patient and control human donors
Commercially available and consented iPSC lines
We have an extensive commercial library iPSCs from a range of patient and healthy donors. The cell lines include those from healthy donors and those with:
- Huntington’s disease
- Amyotrophic Lateral Sclerosis (ALS)
- Alzheimer’s disease
- Friedreich’s ataxia
- Frontotemporal dementia
- Parkinson’s disease
- See all
Our axoLinesTM iPSCs are used for axoServicesTM custom lab services, custom differentiated axoCellsTM projects and specific licensing arrangements.
A library of high-quality iPSC-derived lines from unaffected and patient donors, the portfolio is strengthened through strategic collaborations including with StrataStem to deliver stratified sporadic Alzheimer’s disease models, the PRISM ALS consortia with LifeArc and ALS TDI to democratise access to diverse, patient-derived ALS models for researchers worldwide and other academic research institutes and patient advocacy groups.
Unaffected donors iPSCs
| Unaffected | CFH p.Y402H +/+; ARMS2 p.A69S +/+; HTRA1 rs1120063 +/+ | M | 30 |
| CFH p. Y402H +/+; ARMS2; p.A69S +/+; HTRA1 rs11200638 +/+ | M | 45 | |
| CFH p.Y402 +/+ | F | 84 | |
| MERTK +/- p.H721Q | F | 51 | |
| ATN1 CAG 12/13 +/+ | F | 45 |
Patient donor iPSCs
| Mutation | Sex | Age | |
| ALS | C9orf72 >100 G4C2 +/- | F | 44 |
| SOD1 p.D109Y +/- | F | 61 | |
| C9orf72 >145 G4C2 +/- | F | 64 | |
| C9orf72 >145 G4C2 +/- | M | 62 | |
| ALS/FTD | TARDBP p.A382T +/- | F | 62 |
| AD | APOE E3/E3 | F | 59 |
| APOE E3/E4 | M | 60 | |
| APOE E3/E4 | F | 52 | |
| APOE E3/E3 | M | 83 | |
| APOE E4/E4 | F | 69 | |
| APOE E3/E3 | M | 80 | |
| APOE E3/E4 | M | 74 | |
| APOE E4/E4 | F | 76 | |
| APOE E3/E4 | M | 82 | |
| APOE E3/E4 | F | 72 | |
| APOE E3/E3 | F | 79 | |
| APOE E3/E3 | M | 70 | |
| APOE E3/E3 | M | 81 | |
| APOE E2/E3 | M | 73 | |
| APOE E3/E4 | M | 70 | |
| APOE E3/E4 | M | 77 | |
| APOE E3/E4 | M | 72 | |
| APOE E2/E3 | M | 77 | |
| APOE E3/E4 | F | 52 | |
| AMD | CFH p.Y402H -/-; ARMS2 p.A69S -/-; C3 p. R102G +/-; APOE E2/E3 | F | 70 |
| CFH p. Y402H -/- | M | 87 | |
| bvFTD | MAPT c.1920+16C>T +/- | M | 68 |
| MAPT c.1920+16C>T +/- | M | 59 | |
| bFTD | MAPT c.1920+16C>T +/- | F | 54 |
| MAPT c.1920+16C>T +/- | F | 42 | |
| MAPT c.1920+16C>T +/- | M | 35 | |
| CMT4J | FIG4 pI41T +/- | M | 27 |
| DRPLA | ATN1 CAG 13/66 +/- | M | 16 |
| ATN1 CAG 17/57 +/- | M | 51 | |
| Friedreich’s ataxia | FXN >75 GAA +/- | M | 21 |
| FXN 8 GAA +/- | M | 44 | |
| FXN >75 GAA +/- | F | 17 | |
| FXN >66 GAA +/- | M | 23 | |
| FXN >75 GAA +/- | M | 34 | |
| FTD | PRGN p.R493* +/- | F | 31 |
| PRGN p.C31FS +/- | M | 65 |
| FTDP | VCP p.R155C +/- | F | 43 |
| VCP p.R191Q +/- | M | 42 | |
| HD | HTT CAG 18/39 +/- | F | 40-50 |
| HTT CAG 17/42 +/- | F | 51 | |
| HTT CAG 14/127 +/- | F | 6 | |
| HTT CAG 14/127 +/- | F | 7 | |
| HTT CAG 28/66 +/- | M | 16 | |
| HTT CAG 17/38 +/- | M | 64 | |
| LCA | CRB1 p.K801* +/-; p.C896* +/- | F | 4 |
| CRB1 p.H447Pfs*7 +/-; p.K801* +/- | F | 4 | |
| Micropthalmia | NM_0012026 c.-7-192G>A | F | 39 |
| ML4 | MCOLN1 p.F262S +/- | F | 36 |
| NHD | TREM2 p.W50C -/- | F | 41 |
| TREM2 p.W50C +/- | M | 68 | |
| SCA3 | ATXN3 CAG 14/69 +/- | M | 50 |
| ATXN3 CAG 26/70 +/- | F | 53 | |
| PD | PINK1 p.W90Lfsx12 -/-; PRKN pR275W +/- | F | 48 |
| PINK1 p.W90Lfsx12 +/-; PRKN p.R275W +/- | M | 75 | |
| PINK1 p.W9OLfsx12 -/- | F | 52 | |
| Retinopathy | BEST1 p.N296S +/- | M | 69 |
| BEST1 p.S231R +/- | M | 20 | |
| BEST1 p.A243V +/- | F | 50 | |
| EFEMP1 p.R345W +/- | F | 58 | |
| EFEMP1 p.R345W +/- | M | 64 | |
| EFEMP1 p.R345W +/- | M | 76 | |
| MERTK p.L623* +/-; p.D723N +/- | F | 24 | |
| MERTK p.R722* / multi-exon deletion +/- | M | 21 | |
| MERTK p.H721Q -/- | F | 18 | |
| SBMA | AR >47 CAG | M | 66 |
| SCA2 | ATXN2 CAG 22/38 +/- | M | 41 |
| ATXN2 CAG 22/36 +/- | M | 58 | |
| ATXN2 CAG 22/39 +/- | F | N/A | |
| ATXN3 CAG 14/75 +/- | F | 22 | |
| CACNA1A CAG 23 +/- | F | 63 | |
| ATXN7 CAG 10/39 +/- | F | 61 | |
| USH1 | MYO7A p.R1240Q +/-; p.K1255RfsTer8 +/- | M | 60 |
| MYO7A p.D75H +/-; p.R2024* +/- | F | N/A |
